^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    JAK2 (Janus kinase 2)

    i
    Other names: JTK10, THCYT3, JAK2, Janus Kinase 2, Tyrosine-Protein Kinase JAK2, JAK-2
    2d
    Role of Chitinase 3-like-1 in Myelofibrosis via Fibroblast-Produced Extracellular Matrix Enhancement. (PubMed, J Cell Physiol)
    Romiplostim-induced MF in a mouse model demonstrated extensive bone marrow (BM) CHI3L1 mRNA expression, which was reversed by clodronate treatment. A culture assay revealed that high CHI3L1 concentrations promoted extracellular matrix production by fibroblast cell lines, and that a CHI3L1-neutralizing antibody abrogated this effect. These results indicate the importance of CHI3L1 in the association between fibrocytes and fibroblasts in MF and could be a focus for future treatment.
    Journal
    |
    JAK2 (Janus kinase 2) • CD14 (CD14 Molecule) • CHI3L1 (Chitinase 3-like 1)
    |
    clodronate disodium • Nplate (romiplostim)
    2d
    Role of oncostatin M and its receptor in the inflammatory pathogenesis of Graves' orbitopathy. (PubMed, Immunopharmacol Immunotoxicol)
    OSM-OSMR signaling amplifies IL-1β-induced inflammatory responses and promotes terminal adipogenic differentiation in GO orbital fibroblasts. This dual regulatory function suggests OSMR as a novel therapeutic target for modulating inflammation and tissue remodeling in GO.
    Journal
    |
    JAK2 (Janus kinase 2) • IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • ICAM1 (Intercellular adhesion molecule 1) • CCL2 (Chemokine (C-C motif) ligand 2) • LIFR (LIF Receptor Subunit Alpha) • IL1B (Interleukin 1, beta) • OSMR (Oncostatin M Receptor) • LIF (LIF Interleukin 6 Family Cytokine)
    3d
    Comparative Analysis of Homologous Recombination Repair Status Across Gynecologic and Breast Cancers in Chinese Populations. (PubMed, Curr Cancer Drug Targets)
    The mutational patterns affecting homologous recombination repair differ across gynecologic and breast cancers. Further research into cancer-specific HRD mechanisms is warranted.
    Journal • Tumor mutational burden • BRCA Biomarker • PARP Biomarker
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • HRD (Homologous Recombination Deficiency) • JAK2 (Janus kinase 2) • PALB2 (Partner and localizer of BRCA2) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • BRCA (Breast cancer early onset) • EPHA5 (EPH Receptor A5)
    |
    TP53 mutation • BRCA2 mutation • BRCA1 mutation • PIK3CA mutation • HRD • PALB2 mutation • BRCA mutation
    3d
    Landscape and functional impact of variants of unknown significance of immune response genes in human cancer. (PubMed, Cancer Gene Ther)
    These findings provide a detailed mutational map of antigen presentation and IFNγ-response components in cancer. Overall, our results provide a resource of specific mutations in genes involved in immune pathways that compromise tumor immunogenicity and will serve for support in patient selection for response to ICB.
    Journal
    |
    JAK2 (Janus kinase 2) • IFNG (Interferon, gamma) • B2M (Beta-2-microglobulin) • JAK1 (Janus Kinase 1) • CALR (Calreticulin) • IFNAR2 (Interferon Alpha And Beta Receptor Subunit 2) • IFNGR1 (Interferon Gamma Receptor 1)
    5d
    Janus kinase 2 regulates Nurr1 protein stability in dopaminergic neurons of the aging midbrain. (PubMed, bioRxiv)
    Together, these findings reveal a phosphorylation-independent mechanism by which JAK2 stabilizes Nurr1 protein and enhances its transcriptional activity. Our results further suggest that age-associated induction of JAK2 in dopaminergic neurons may promote neuronal resilience by maintaining Nurr1 protein stability during aging.
    Journal
    |
    JAK2 (Janus kinase 2) • NR4A2 (Nuclear Receptor Subfamily 4 Group A Member 2)
    5d
    Mutational architecture defines disease behaviour in an Indian cohort of Myeloproliferative Neoplasms: Foundations for a Genomics-first classification. (PubMed, Leuk Res)
    Survival differences were independent of WHO diagnostic labels, with molecular architecture alone consistently predicting outcomes across all clusters In this Indian MPN cohort, molecular architecture, not WHO label, dictated prognosis. The reproducible impact of high-risk co-mutations demonstrates both the feasibility and need for a genomics-first, tiered classification to guide risk stratification and therapy.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • ABL1 (ABL proto-oncogene 1) • JAK2 (Janus kinase 2) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2)
    |
    TMB-H
    6d
    Pleione bulbocodioides Polysaccharides Reprogram Tumor-Associated Macrophages via JAK2/STAT3 Inhibition to Suppress Hepatocellular Carcinoma. (PubMed, J Hepatocell Carcinoma)
    PBPs suppress HCC progression in association with modulation of TAM polarization and inhibition of JAK2/STAT3 signaling. These findings provide mechanistic insight into the immunomodulatory actions of PBPs and support their further investigation as macrophage-targeting agents for HCC.
    Journal
    |
    JAK2 (Janus kinase 2) • IL10 (Interleukin 10) • IL13 (Interleukin 13) • IL4 (Interleukin 4)
    6d
    Neutrophil-to-lymphocyte ratio half reduction as a surrogate of molecular response in polycythemia vera treated with ropeginterferon alfa-2b. (PubMed, Ther Adv Hematol)
    NLR half reduction significantly predicted hematologic response (week 24 OR 6.42, p = 0.001) and molecular response consistently across all time points (week 24 OR 27.94, p < 0.001). NLR half reduction is a simple, cost-effective biomarker that may reflect molecular response and treatment efficacy in PV.
    Journal
    |
    JAK2 (Janus kinase 2)
    |
    Besremi (ropeginterferon alfa-2b-njft)
    6d
    Hexane extract of Pittosporopsis kerrii Craib mitigates LPS-driven inflammatory responses via JAK/STAT1 pathway inhibition in RAW 264.7 macrophages. (PubMed, Fitoterapia)
    PK-H exerts anti-inflammatory effects predominantly through selective inhibition of the JAK-STAT1 pathway. Its diterpenoid constituents represent promising leads for STAT1-targeted anti-inflammatory agents.
    Journal
    |
    JAK2 (Janus kinase 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • JAK1 (Janus Kinase 1) • IFNGR1 (Interferon Gamma Receptor 1)
    7d
    Ruxolitinib reverses systemic vasculitis driven by JAK2 V617F-mutated essential thrombocythemia: a case report. (PubMed, Front Immunol)
    Treatment with hydroxycarbamide and ruxolitinib resulted in decreased platelet counts and improved vasculitis, with no subsequent recurrence of cardiovascular events. This rare case shows that ruxolitinib can be effective in treating vasculitis complications in patients with JAK2 mutation-positive ET.
    Journal
    |
    JAK2 (Janus kinase 2)
    |
    Jakafi (ruxolitinib) • hydroxyurea